This content is restricted.
Brief
"On 12/02/2025, the Italian Medicines Agency (AIFA) Board of Directors approved the reimbursability by the National Health Service for 6 medicines. This includes 1 orphan medicine, TALVEY, for treating relapsed and refractory multiple myeloma in adults, as well as 3 generic medications: APIXABAN MYLAN, IDROSSICARBAMIDE AUROBINDO, and MARAVIROC WAYMADE, and 2 extended indications: TALZENNA and IMCIVREE."
Highlights content goes here...
This content is restricted.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
